JPMorgan Chase & Co. downgraded shares of Medidata Solutions (NASDAQ:MDSO) from a neutral rating to an underweight rating in a research note published on Thursday morning, MarketBeat reports.
A number of other research analysts have also recently issued reports on MDSO. BidaskClub raised Medidata Solutions from a buy rating to a strong-buy rating in a report on Thursday, August 16th. ValuEngine raised Medidata Solutions from a hold rating to a buy rating in a report on Friday, August 24th. Royal Bank of Canada cut their price target on Medidata Solutions to $91.00 and set an outperform rating for the company in a report on Tuesday, September 25th. Zacks Investment Research cut Medidata Solutions from a hold rating to a sell rating in a report on Tuesday, October 16th. Finally, Piper Jaffray Companies cut their price target on Medidata Solutions from $96.00 to $93.00 in a report on Thursday, October 18th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $85.10.
Shares of NASDAQ MDSO opened at $71.34 on Thursday. The firm has a market cap of $4.37 billion, a price-to-earnings ratio of 74.31, a P/E/G ratio of 4.22 and a beta of 1.30. Medidata Solutions has a 52-week low of $59.60 and a 52-week high of $88.87. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.52 and a quick ratio of 2.52.
In related news, CFO Rouven Bergmann sold 10,000 shares of Medidata Solutions stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $79.00, for a total value of $790,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael Pray sold 7,000 shares of Medidata Solutions stock in a transaction dated Monday, November 26th. The stock was sold at an average price of $73.02, for a total value of $511,140.00. Following the completion of the sale, the executive vice president now owns 52,408 shares of the company’s stock, valued at $3,826,832.16. The disclosure for this sale can be found here. Over the last quarter, insiders sold 34,030 shares of company stock valued at $2,539,022. Corporate insiders own 4.70% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Man Group plc acquired a new stake in Medidata Solutions in the third quarter worth about $205,000. Quantbot Technologies LP acquired a new position in shares of Medidata Solutions during the 3rd quarter worth about $229,000. First Republic Investment Management Inc. acquired a new position in shares of Medidata Solutions during the 2nd quarter worth about $242,000. Gideon Capital Advisors Inc. acquired a new position in shares of Medidata Solutions during the 3rd quarter worth about $263,000. Finally, Zions Bancorporation acquired a new position in shares of Medidata Solutions during the 2nd quarter worth about $274,000.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.
Further Reading: Marijuana Stocks
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.